Gujarat Inject (Kerala) News

Gujarat Inject Director Reena Mahatma Resigns

Gujarat Inject (Kerala) Limited announces resignation of Independent Director Mrs. Reena Mahatma effective December 9, 2025, citing pre-occupation and personal commitments as reasons for departure.

Gujarat Inject Kerala Limited Independent Director Resigns

Mrs. Reena Mahatma resigned as Non-Executive Independent Director of Gujarat Inject Kerala Limited effective December 9, 2025, citing pre-occupation and personal commitments. The resignation affects the board composition of the company, which has cleared all her dues and accepted her resignation from close of business hours on December 8, 2025.

Gujarat Inject Kerala Limited Reports Q2 FY26 Financial Results with Revenue of Rs 361.09 Lakh

Gujarat Inject Kerala Limited announced its unaudited financial results for the second quarter and half-year ended September 30, 2025. The company reported revenue from operations of Rs 361.09 lakh for Q2, compared to Rs 399.75 lakh in the previous quarter and Rs 1,165.63 lakh in the corresponding quarter of the previous year. Total income for the quarter stood at Rs 363.38 lakh. The company recorded a profit after tax of Rs 6.75 lakh for the quarter, with basic earnings per share of Rs 0.05. For the half-year period, revenue from operations was Rs 760.84 lakh with a profit after tax of Rs 67.76 lakh. The Board of Directors approved these results at their meeting held on November 13, 2025. The company's statutory auditors M/s. S. Mandawat & Co. conducted a limited review of the financial results.

Gujarat Inject Kerala Ltd Reports Q1 FY2026 Financial Results

Gujarat Inject Kerala Ltd approved its unaudited standalone financial results for the first quarter ended June 30, 2025. The company reported revenue from operations of ₹242.12 lakh, down from ₹304.54 lakh in the same quarter last year. Net profit for the quarter stood at ₹7.35 lakh compared to ₹12.23 lakh in Q1 FY2025. Basic earnings per share was ₹0.05 versus ₹0.08 in the corresponding previous quarter. Total expenses were ₹232.30 lakh, primarily driven by purchases of stock-in-trade worth ₹225.86 lakh. The company operates in trading of cloths and commission income from pharma business. The board meeting was held on August 14, 2025, and the results were reviewed by statutory auditors S. Mandawat & Co.